FITC Anti-Integrin beta 4 antibody [450-9D] (ab22486)

Submit a review Q&A (2)References (3)
Immunohistochemistry (Frozen sections) - FITC Anti-Integrin beta 4 antibody [450-9D] (ab22486)

    Key features and details

    • FITC Mouse monoclonal [450-9D] to Integrin beta 4
    • Suitable for: IHC-Fr
    • Reacts with: Human
    • Conjugation: FITC. Ex: 493nm, Em: 528nm
    • Isotype: IgG1

    Overview

    • Product name

      FITC Anti-Integrin beta 4 antibody [450-9D]
      See all Integrin beta 4 primary antibodies

    • Description

      FITC Mouse monoclonal [450-9D] to Integrin beta 4

    • Host species

      Mouse

    • Conjugation

      FITC. Ex: 493nm, Em: 528nm

    • Specificity

      ab22486 recognises the integrin beta 4 expressed on epithelial cells, Schwann cells and various tumour cell lines.

    • Tested applications

      Suitable for: IHC-Frmore details

    • Species reactivity

      Reacts with: Human

    • Immunogen

      Full length native protein (purified) (Human): Purified a6b4 integrin from A431 cells

    • Epitope

      the epitope is in the extracellular region of Integrin beta 4

    • Positive control

      • Human tonsil

    • General notes

      Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.

      Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.

      We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.

      In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.

      We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.

      Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.

      Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.

    Properties

    • Form

      Liquid

    • Storage instructions

      Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.

    • Storage buffer

      pH: 7.40
      Preservative: 0.1% Sodium azide
      Constituents: PBS, 1% BSA
    • Concentration information loading...

    • Purity

      Protein G purified

    • Purification notes

      ab22486 has been purified by affinity chromatography on Protein G from tissue culture supernatant.

    • Clonality

      Monoclonal

    • Clone number

      450-9D

    • Myeloma

      Sp2/0

    • Isotype

      IgG1

    • Research areas

    Applications

    Our Abpromise guarantee covers the use of ab22486 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Abreviews Notes
    IHC-Fr Use at an assay dependent concentration.

    Target

    • Function

      Integrin alpha-6/beta-4 is a receptor for laminin. It plays a critical structural role in the hemidesmosome of epithelial cells.

    • Tissue specificity

      Integrin alpha-6/beta-4 is predominantly expressed by epithelia. Isoform beta-4D is also expressed in colon and placenta. Isoform beta-4E is also expressed in epidermis, lung, duodenum, heart, spleen and stomach.

    • Involvement in disease

      Defects in ITGB4 are a cause of epidermolysis bullosa letalis with pyloric atresia (EB-PA) [MIM:226730]; also known as junctional epidermolysis bullosa with pyloric atresia (PA-JEB) or aplasia cutis congenita with gastrointestinal atresia. EB-PA is an autosomal recessive, frequently lethal, epidermolysis bullosa with variable involvement of skin, nails, mucosa, and with variable effects on the digestive system. It is characterized by mucocutaneous fragility, aplasia cutis congenita, and gastrointestinal atresia, which most commonly affects the pylorus. Pyloric atresia is a primary manifestation rather than a scarring process secondary to epidermolysis bullosa.
      Defects in ITGB4 are a cause of generalized atrophic benign epidermolysis bullosa (GABEB) [MIM:226650]. GABEB is a non-lethal, adult form of junctional epidermolysis bullosa characterized by life-long blistering of the skin, associated with hair and tooth abnormalities.

    • Sequence similarities

      Belongs to the integrin beta chain family.
      Contains 1 Calx-beta domain.
      Contains 4 fibronectin type-III domains.
      Contains 1 PSI domain.
      Contains 1 VWFA domain.

    • Domain

      The fibronectin type-III-like domains bind BPAG1 and plectin and probably also recruit BP230.

    • Cellular localization

      Membrane.
    • Information by UniProt

    • Database links

      • Alternative names

        • CD 104 antibody
        • CD104 antibody
        • CD104 antigen antibody
        • gp150 antibody
        • Integrin beta 4 subunit antibody
        • Integrin beta-4 antibody
        • ITB4_HUMAN antibody
        • ITG B4 antibody
        • ITGB 4 antibody
        • Itgb4 antibody
        see all

      Images

      • Immunohistochemistry (Frozen sections) - FITC Anti-Integrin beta 4 antibody [450-9D] (ab22486)
        Immunohistochemistry (Frozen sections) - FITC Anti-Integrin beta 4 antibody [450-9D] (ab22486)

        Immunohistochemistry (Frozen sections) analysis of human tonsil tissue section labeling Integrin beta 4 with ab22486. 

      References (3)

      Publishing research using ab22486? Please let us know so that we can cite the reference in this datasheet.

      ab22486 has been referenced in 3 publications.

      • Gamage TKJB  et al. Human trophoblasts are primarily distinguished from somatic cells by differences in the pattern rather than the degree of global CpG methylation. Biol Open 7:N/A (2018). PubMed: 30026266
      • James JL  et al. Isolation and characterisation of a novel trophoblast side-population from first trimester placentae. Reproduction 150:449-62 (2015). PubMed: 26248480
      • DaSilva-Arnold S  et al. Differentiation of first trimester cytotrophoblast to extravillous trophoblast involves an epithelial-mesenchymal transition. Placenta 36:1412-8 (2015). PubMed: 26545962

      Customer reviews and Q&As

      Show All Reviews Q&A
      Submit a review Submit a question

      1-2 of 2 Abreviews or Q&A

      Question

      BATCH NUMBER -- 191982. -- ORDER NUMBER -- order was placed on 23rd or 24th of June-- DESCRIPTION OF THE PROBLEM No bands. When I used a rabbit polyclonal antibody against the same I could get proper signal SAMPLE Human whole cell lysate from C4-2 PRIMARY ANTIBODY ABCAM mouse monoclonal DETECTION METHOD Pierce POSITIVE AND NEGATIVE CONTROLS USED Nothing ANTIBODY STORAGE CONDITIONS As recommended SAMPLE PREPARATION RIPA lysis buffer from SCBT AMOUNT OF PROTEIN LOADED 60 micrograms ELECTROPHORESIS/GEL CONDITIONS Reducing, 8% 50 volts for 45 minutes and 2and half hour at 80 volts TRANSFER AND BLOCKING CONDITIONS 0.05% SDS in TRIS-Glysine buffer at 4 degree centigrade and 380mA for 21/2 hours( This is very standard procedure I followd for all my investigation with integrins. SECONDARY ANTIBODY Mouse IgG SCBT HOW MANY TIMES HAVE YOU TRIED THE APPLICATION? one HAVE YOU RUN A "NO PRIMARY" CONTROL? No WHAT STEPS HAVE YOU ALTERED? Nothing. I followed the same protocol that has been working for me with polyconal antibodies.

      Read More
      Answer

      Further to previous correspondence I have been in touch with the source of this antibody. I am concerned that this antibody has in fact NOT been tested and shown to work by western blotting. It is FITC labeled and therefore my concern was that the fluorophore label was occluding the capacity for the secondary to recognise the primary antibody. Given that it is yet to be tested I am certainly prepared to offer you a credit note against this purchase provided that the antibody was purchased within the past 90 days. If this is the case please email me details of the order including the order number and date of purchase. I look forward to hearing from you.

      Read More

      Question

      BATCH NUMBER -- 191982. -- ORDER NUMBER -- order was placed on 23rd or 24th of June-- DESCRIPTION OF THE PROBLEM No bands. When I used a rabbit polyclonal antibody against the same I could get proper signal SAMPLE Human whole cell lysate from C4-2 PRIMARY ANTIBODY ABCAM mouse monoclonal DETECTION METHOD Pierce POSITIVE AND NEGATIVE CONTROLS USED Nothing ANTIBODY STORAGE CONDITIONS As recommended SAMPLE PREPARATION RIPA lysis buffer from SCBT AMOUNT OF PROTEIN LOADED 60 micrograms ELECTROPHORESIS/GEL CONDITIONS Reducing, 8% 50 volts for 45 minutes and 2and half hour at 80 volts TRANSFER AND BLOCKING CONDITIONS 0.05% SDS in TRIS-Glysine buffer at 4 degree centigrade and 380mA for 21/2 hours( This is very standard procedure I followd for all my investigation with integrins. SECONDARY ANTIBODY Mouse IgG SCBT HOW MANY TIMES HAVE YOU TRIED THE APPLICATION? one HAVE YOU RUN A "NO PRIMARY" CONTROL? No WHAT STEPS HAVE YOU ALTERED? Nothing. I followed the same protocol that has been working for me with polyconal antibodies.

      Read More
      Answer

      Thank you for your enquiry. I am sorry to hear that you have been having difficulties with this antibody. I appreciate the controls that you have in place and that you are detecting Integrin beta 4 using an alternatively sourced antibody. Please can you detail the antibody dilutions that you have applied the antibody at and whether the alternative antibody was applied in parallel to control for variation in your experimental procedure. I am in touch with the lab to determine the conditions employed as my concern is that given this antibody is FITC conjugated and may occlude the binding of a secondary antibody. I look forward to hearing from you.

      Read More

      Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
      For licensing inquiries, please contact partnerships@abcam.com